Brainsway Ltd.

Foreign Filer Report • Aug 11, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2021

Commission File Number: 001-35165

BRAINSWAY LTD.

(Translation of registrant's name into English)

19 Hartum Street Bynet Building, 3rd Floor Har HaHotzvim Jerusalem, 9777518, Israel (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXHIBIT INDEX

Exhibit Title

99.1 BrainsWay Reports Second Quarter 2021 Financial Results and Operational Highlights

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BRAINSWAY LTD.

(Registrant)

Date: August 11, 2021 /s/ Christopher R. von Jako, Ph.D Christopher R. von Jako, Ph.D President and Chief Executive Officer

BrainsWay Reports Second Quarter 2021 Financial Results and Operational Highlights

Strong Revenue Growth of 45% Year-over-Yearin Q2 2021

Gained Meaningful Traction in Reimbursement for Deep TMS™ in both OCD and Depression

Conference Call to be held Today at 8:30 AM ET

BURLINGTON, Mass. and JERUSALEM, Aug. 11, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported second quarter 2021 financial results and provided an operational update.

Recent Financial and Operational Highlights

• For the three months ended June 30, 2021, revenues were \$7.0 million, a 45% increase as compared to the same period in 2020.
• As ofJune 30, 2021, BrainsWay's Deep TMS™ installed base was 682 total systems, a 20% increase from the installed base at the same point in the prior year.
• As ofJune 30, 2021, the total number of OCD add-on helmetsshipped was 247, representing OCD treatment capability on 36% of the Company's installed base.
• Achieved significant progressin reimbursement for Deep TMS in the treatment of OCD and depression
  • Received key positive coverage policies in OCD from Centene and Health Care Service Corporation (HCSC), a leading Blue Cross Blue Shield licensee, which collectively represent approximately 42 million covered lives
  • First draft Local Coverage Determination (LCD) published applicable to OCD by the Medicare Administrative Contractor (MAC), Palmetto GBA, which represents over 9 million covered lives
  • Multiple smaller private payors covering the Company's depression treatment have continued the trend of decreasing the number of required prior medication failures from three or four to two
• Received encouraging early data from completing patients in the Company's controlled market release of Deep TMS for smoking addiction
• Initiated the Company'slargest patient awareness campaign to date; early results have yielded an over 300% increase in patient inquiries for Deep TMS treatment during June and July

"We are pleased with ourstrong performance in the second quarter and the increasingly positive trends impacting our company," stated Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. "Our revenues of \$7.0 million represented a substantial 45% increase over the pandemicimpacted second quarter of 2020, as our business continues to demonstrate significant momentum."

"Importantly, we are beginning to gain meaningful traction in OCD reimbursement, which we believe will be an important long-term growth driver in enhancing patient access to Deep TMS. Specifically, we received key positive coverage policies from Centene and HCSC, which collectively represent approximately 42 million covered lives. In addition, the first draft LCD was published proposing coverage applicable to the Deep TMS system for the treatment of OCD by Palmetto, a regional Medicare administrator, which represents over 9 million covered lives. This progress in reimbursement is already driving further interest in this strategic indication, with approximately two-thirds of recently shipped systems including an OCD add-on helmet. Moreover, we ended the second quarter with \$55.9 million in cash, allowing us to operate the business from a position of financial strength," concluded Dr. von Jako.

Second Quarter 2021 Financial Results

• Total revenues for the second quarter of 2021 were \$7.0 million, compared to \$4.8 million in the second quarter of 2020, an increase of 45%. Quarterly recurring lease revenues were \$3.6 million, slightly higher than the second quarter of 2020, and comprising approximately 51% of total revenues.
• Gross margin for the second quarter of 2021 was 81%, compared to 79% for the second quarter of 2020.
• Operating expenses for the second quarter of 2021 were \$7.2 million compared to \$4.0 million for the second quarter of 2020.
• For the three months ended June 30, 2021, operating loss was \$1.5 million compared to an operating loss of \$215 thousand during the same period in the prior year.
• As of June 30, 2021, the Company had cash and short-term deposits of approximately \$55.9 million, compared to \$17.2 million at December 31, 2020.

Conference Call and Webcast

BrainsWay's management will host a conference call today, August 11, 2021, at 8:30 a.m. Eastern Time to discuss these results and answer questions.

Wednesday, August 11, at 8:30 AM Eastern Time:

United States:	877-407-3982
International:	201-493-6780
Conference ID:	13722002
Webcast:	http://public.viavid.com/index.php?id=146013

To listen to a live webcast, please visit the Investors section of the BrainsWay website at www.BrainsWay.com. Please access the Company's website at least 10 minutes ahead of the conference call to register. The webcast replay will be available on the website for two weeks following the completion of the call.

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company's anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company'sintellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, and the effect of the global COVID-19 health pandemic on our business and continued uncertainty and market impact relating thereto.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward- looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 20-F. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.

Contacts:

BrainsWay: Scott Areglado SVP and Chief Financial Officer 844-386-7001 Scott.Areglado@BrainsWay.com

Investors: Bob Yedid LifeSci Advisors 646-597-6989 Bob@LifeSciAdvisors.com

BRAINSWAY LTD. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION U.S. dollarsin thousands (exceptshare and per share data)

	June 30,			December 31,
		2021		2020
ASSETS
Current Assets
Cash and cash equivalents	\$	15,596	\$	16,961
Short-term deposits		40,275		221
Trade receivables, net		6,676		5,582
Other accounts receivable		2,362		1,534
Total current assets		64,909		24,298
Long-term deposits		280		163
Leased systems		4,429		5,198
System components and other property and equipment		4,867		4,352
Total assets	\$	74,485	\$	34,011
LIABILITIES AND EQUITY
Current Liabilities
Trade payables	\$	732	\$	781
Other accounts payable		3,977		3,769
Deferred revenue		1,556		1,543
Liability in respect of research and development grants		745		707
Total current liabilities		7,010		6,800
Deferred revenue and other liabilities		2,136		2,015
Liability in respect of research and development grants		5,666		5,524
Warrants		7		38
Total Liabilities		14,819		14,377
Equity:
Share capital		346		233
Share premium		137,344		95,135
Share-based payment		4,769		3,748
Adjustments arising from translating financial statements from functional
currency to presentation currency		(2,188)		(2,188)
Accumulated deficit		(80,605)		(77,294)
Total Equity		59,666		19,634
Total Liabilities and Equity	\$	74,485	\$	34,011

BRAINSWAY LTD. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS U.S. dollarsin thousands (exceptshare and per share data)

	For the six months ended June 30,			For the three months ended June 30,
		2021		2020		2021		2020
Revenues	\$	13,126	\$	8,977	\$	7,005	\$	4,820
Cost of revenues		2,763		2,007		1,300		992
Gross profit		10,363		6,970		5,705		3,828
Research and development expenses, net		2,575		2,836		1,650		1,041
Selling and marketing expenses		7,320		5,891		4,191		2,178
General and administrative expenses		2,782		2,079		1,377		824
Total operating expenses		12,677		10,806		7,218		4,043
Operating loss		(2,314)		(3,836)		(1,513)		(215)
Finance (expense) income, net		(681)		130		(269)		(179)
Loss before income taxes		(2,995)		(3,706)		(1,782)		(394)
Income taxes		316		307		156		177
Net loss and total comprehensive loss	\$	(3,311)	\$	(4,013)	\$	(1,938)	\$	(571)
Basic and diluted net comprehensive loss per share	\$	0.11	\$	0.18	\$	0.06	\$	0.03

BRAINSWAY LTD. CONSOLIDATED STATEMENTS OF CASH FLOWS U.S. dollars in thousands

2021 2020 2021 2020 Cash flowsfrom operating activities: Net loss and total comprehensive loss \$ (3,311) \$ (4,013) \$ (1,938) \$ (571) Adjustmentsto reconcile net lossto net cash (used in) provided by operating activities: Adjustmentsto profit or lossitems: 761 729 358 284 Depreciation and amortization Depreciation of leased systems 580 585 288 291 681 (130) 269 179 Finance expenses (income), net Cost ofshare based payment 1,083 437 280 129 Income taxes 316 307 156 177 Changes in asset and liability items: Decrease (increase) in trade receivables (1,131) 358 (38) 270 Decrease (increase) in other accounts (999) 230 (34) (1,017) receivable Increase (decrease) in trade payables (86) 178 (377) 591 Increase (decrease) in other accounts payable (200) (677) 12 (751) Increase in deferred revenues and other 212 37 50 52 liabilities Cash paid and received during the period for: Interest paid (30) (43) (10) (20) Interest received 50 19 2 - Taxes paid (12) (9) 148 - Cash (used in) provided by operating activities: (2,134) (1,961) (1,819) 616 Cash flowsfrom investing activities: Purchase of property and equipment(*) (917) (1,911) (538) (965) Investment in short-term deposits, net (40,000) - (40,000) - withdrawal of (investment in) (11) 7 (11) (3) Withdrawal of long-term deposits, net Net cash used in investing activities (40,928) (1,904) (40,549) (968) Cash flowsfrom financing activities: Repayment of liability in respect of research (373) - (373) - and development grants Receipt of government grants 167 42 77 - Repayment of lease liability (227) (221) (227) (111) 42,260 Issuance ofshare capital - - - Net cash provided by (used in) financing activities 41,827 (179) (523) (111)	For the six months ended June 30,			For the three months ended June 30,

Exchange rate differences on cash and cash equivalents	(130)	(17)	207	107
Decrease in cash and cash equivalents	(1,365)	(4,061)	(42,684)	(356)
Cash and cash equivalents at the beginning of the period	16,961	21,674	58,280	17,969
Cash and cash equivalents at the end of the period	\$ 15,596	\$ 17,613	\$ 15,596	\$ 17,613
(a) Significant non cash transactions:
Purchase of property and equipment on credit	-	515	-	323
Recognition of new lease liability and right of-use	183	-	183	-
(*) Derived mainly from purchase ofsystem components